Turning Point Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Turning Point Therapeutics, Inc. Turning Point Therapeutics, Inc. (TPTX) is a clinical-stage precision oncology biopharmaceutical company focused on designing and developing next-generation tyrosine kinase inhibitors (TKIs) that target genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients, including ROS1, NTRK, ALK, RET, MET, SRC, and CSF1R alterations associated with non-small cell lung cancer, solid tumors, and other advanced malignancies; its lead product candidate, repotrectinib, a ROS1/TRK inhibitor in Phase 2 for advanced solid neoplasms with FDA approval achieved in November 2023 in the United States, alongside elzovantinib (TPX-0022, MET/SRC/CSF1R inhibitor in Phase 1/2 SHIELD-1 trial), TPX-0046 (RET inhibitor in Phase 1/2 SWORD-1 trial), TPX-0131 (ALK inhibitor in Phase 1/2 FORGE-1 trial), and earlier-stage candidates like LM-302 (CLDN18.2 ADC in Phase 1) and preclinical assets such as TPX-02226. Founded in 2013 and headquartered in San Diego, California, the company operates primarily in the United States with a global pipeline development strategy targeting patients across major oncology markets. In 2022, Bristol Myers Squibb Company acquired Turning Point Therapeutics for $4.1 billion in an all-cash deal at $76 per share, completed in August 2022, integrating its precision oncology platform as a wholly owned subsidiary and accelerating commercialization efforts for repotrectinib while advancing the broader pipeline; recent developments include a five-year strategic alliance with MD Anderson Cancer Center to evaluate repotrectinib and elzovantinib in combination therapies for solid tumors such as non-small cell lung and gastrointestinal cancers, completion of Phase 1 enrollment for elzovantinib's intermediate dose, and pipeline expansion through acquisition of assets like TPX-4589 for gastrointestinal indications as of early 2022, with ongoing trials and preclinical advancements noted through 2024-2025 including new Phase 1/2 initiations for CSF-1R programs.
Company News
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Turning Point Therapeutics, Inc. Buyout
Turning Point Therapeutics' Shares Soar on Bristol-Myers Squibb Deal
SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.
Here is Why Turning Point Therapeutics Jumped 110%
Turning Point Therapeutics shares more than doubled on Friday
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
Turning Point Stock Doubles After Bristol Myers Announces Takeover
Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal
Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Is Turning Point Therapeutics Stock at a Turning Point?
Best Biotech Stocks To Buy Now? 5 To Know